Insulin therapy for improving cardiac surgical outcomes

Current Drug Targets

Volumn 10, Issue 6, 2009, Pages 499-504

  Albacker, Turki ^a,b   Lachapelle, Kevin ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cardiac surgery; Diabetes mellitus; Insulin therapy; Surgical outcomes

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOSE; GLUCOSE PLUS INSULIN PLUS POTASSIUM; GLYCERYL TRINITRATE; INOTROPIC AGENT; INSULIN; ISOPHANE INSULIN; PERIPHERAL VASODILATING AGENT; PLACEBO; POTASSIUM; UNCLASSIFIED DRUG;

AORTA BALLOON; BLOOD GLUCOSE MONITORING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED DRUG THERAPY; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; EARLY INTERVENTION; EXTRACORPOREAL CIRCULATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HEART SURGERY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; INTERMETHOD COMPARISON; LOW DRUG DOSE; MEMBRANE STABILIZATION; NONHUMAN; OXYGEN CONSUMPTION; POSTOPERATIVE COMPLICATION; REVIEW; SIDE EFFECT; SURGICAL MORTALITY; SURGICAL PATIENT; TACHYCARDIA; THERAPY EFFECT; TREATMENT OUTCOME;

ANIMALS; CARDIAC SURGICAL PROCEDURES; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; HUMANS; INSULIN; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 68349133242     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009788488431     Document Type: Review

References (69)

1. Braimbridge MV, Clement AJ, Hedley Brown A, Sabar E, Mendel D. Triple starr valve replacement. Br Med J 1969; 3: 683-688.
2. Svedjeholm R, Huljebrant I, Håkanson E, Vanhanen I. Glutamate and high dose Glucose-Insulin-Potassium (GIK) in the treatment of severe cardiac failure after cardiac operations. Ann Thorac Surg 1995; 59: S23-S30.
3. Lazar HL, Phillipides G, Fitzgerald C. Glucose-insulinpotassium solutions enhance recovery after urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1997; 113: 354-362.
4. Taegtmeyer H, Goodwin GW, Doenst T, Frasier OH. Substrate metabolism as a determinant for postischemic functional recovery of the heart. Am J Cardiol 1997; 80: 3A.
5. Lazar H, Chipkin S, Philippides G, Bao Y, Apstein C. GlucoseInsulin- Potassium solutions improve outcomes in diabetics who have coronary artery operations. Ann Thorac Surg 2000; 70: 145-150.
6. Lazar HL, Chipkin SR, Fitzgerald CA. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004; 9: 1497-1502.
7. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Eng J Med 2001; 345: 1359.
8. Albacker TB, Carvalho G, Schricker T, Lachapelle K. Myocardial protection during elective coronary artery bypass grafting using high-dose insulin therapy. Ann Thorac Surg 2007; 84: 1920-1927.
9. Carson JL, Scholz PM, Chen AY, Peterson ED, Gold J, Schneider SH. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary bypass graft surgery. J Am Coll Cardiol 2002; 40: 418-423.
10. Lolley DM, Myers WO, Ray JF, Sautter RD, Tewksbury DA. Clinical experience with preoperative myocardial nutrition management. J Cardiovasc Surg 1985; 26: 236-243.
11. Gradinac S, Coleman GM, Taegtmeyer H, Sweeney MS, Frazier OH. Improved cardiac function with glucose-insulin-potassium after coronary bypass surgery. Ann Thorac Surg 1989; 48: 484-489.
12. Girard C, Quentin P, Bouvier H, Blanc P, Bastien O, Lehot JJ, et al. Glucose and insulin supply before cardiopulmonary bypass in cardiac surgery: a double-blind study. Ann Thorac Surg 1992; 54: 259-263.
13. DeFronzo R, Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
14. Jagasia D, Whiting JM, Concato J, Pfau S, McNulty PH. Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation 2001; 103(13): 1734-1739.
15. Liao P, DeSantis AJ, Schmeltz LR, Schmidt K, O'Shea-Mahler E, Victor S, et al. Insulin resistance following cardiothoracic surgery in patients with and without a preoperative diagnosis of type 2 diabetes during treatment with intravenous insulin therapy for postoperative hyperglycemia. J Diabetes Complications 2008; 22(4): 229-34.
16. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 335: 773-778.
17. Zindrou D, Taylor KN, Bagger JP. Admission plasma glucose: independent risk factor in non-diabetic women after coronary artery bypass grafting. Diabetes Care 2001; 24: 1634-1639.
18. Fishleder BL. Estudios experimentales a nivelcelular del tratamiento polarizante. Arch Inst Cardiol Mex 1964; 34: 681.
19. Zhang YH, Hancox JC. A novel, voltage-dependent nonselective cation current activated by insulin in guinea pig isolated ventricular myocytes. Circ Res 2003; 92(7): 765-768.
20. Lolley DM, Ray JF III, Myers WO, Sheldon G, Sautter RD. Reduction of intraoperative myocardial infarction by means of exogenous anaerobic substrate enhancement: prospective randomized study. Ann Thorac Surg 1978; 26: 515-24.
21. Salerno T, Wasan SM, Charrette EJP. Glucose substrate in myocardial protection. J Thor Cardiovasc Surg.J Thor Cardiovasc Surg 1980; 79: 59-62.
22. Haider W, Benzer H, Schütz W, Wolner E. Improvement of cardiac preservation by preoperative high insulin supply. J Thorac Cardiovasc Surg 1984; 88: 294-300.
23. Opie LH, Hansey M, Kennelly BM. Proposed metabolic vicious circle in patients with large myocardial infarcts and high plasma-free-fatty-acid concentrations. Lancet 1977; 2: 890-892.
24. Taegtmeyer H. Is there a rationale for glucose-insulin-potassium therapy in acute myocardial infarction? Cardiol Rev 1995; 3: 307-313.
25. Taegtmeyer H, Villalobos DH. Metabolic support for the postischaemic heart.Lancet 1995; 345: 1552-1555.
26. Oldfield GS, Commerford PJ, Opie LH. Effects of preoperative glucose-insulin-potassium on myocardial glycogen levels and on complications of mitral valve replacement.J Thorac Cardiovasc Surg 1986; 91: 874-878.
27. Neely JR, Grotyohann LW. Role of glycolytic products in damage to myocardium: dissociation of adenosine triphosphate levels and recovery of function of reperfused canine myocardium. Circ Res 1984; 55: 816-824.
28. Lagerstrom CF, Walker WE, Taegtmeyer H. Failure of glycogen depletion to improve left ventricular function of the rabbit heart after hypothermic ischemic arrest.Circ Res 1988; 63: 81-86.
29. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Prob Cardiol 1994; 19: 57-116.
30. Goodwin GW, Arteaga JR, Taegtmeyer H. Glycogen Turnover in the Isolated Working Rat Heart. J Biol Chem 1995l; 270(16): 9234-9240.
31. Lopaschuk GD, Wambolt RB, Barr RL. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther 1993; 264(1): 135-144.
32. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994; 1213: 263-276.
33. Lopaschuk GD. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Cor Artery Dis 2001; 12: S8-11.
34. Goodwin GW, Ahmad F, Doenst T, Taegtmeyer H. Energy provision from glycogen, glucose and fatty acids upon adrenergic stimulation of isolated working rat heart. Am J Physiol 1998; 274: 1239-1247.
35. Wittnich C, Dewar ML, Chiu R. Myocardial protection: heparin-induced free fatty acid elevation during cardiopulmonary bypass and its prevention. J Surg Res 1984; 36: 527-531.
36. Gamble J, Lopaschuk GD. Insulin inihibition of 5′ adenosine monophosphate-activated protein kinase in the heart results in activation of acetyl coenzyme A carboxylase and inhibition of fatty acid metabolism. Metabolism 1997; 46: 1270-1274.
37. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol 1974; 36: 413-439.
38. Weiss J, Hiltbrand B. Functional compartmentation of glycolytic versus oxidative metabolism in isolated rabbit heart. J Clin Invet 1985; 75: 436-447.
39. Neely JR, Whitmer JT, Rovetto MJ. Effect of coronary blood flow on glycolytic flux and intracellular pH in isolated rat hearts. Circ Res 1975; 37: 733-741.
40. Jonassen AK, Aasum E, Riemersma RA, Mjøs OD and Larsen TS. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drug Ther 2001; 14: 615-623.
41. Russell R, Taegtmeyer H. Anaplerosis improves fuel oxidation and function in isolated working rat hearts. Circulation 1990; 82: III213.
42. Apstein CS, Taegtmeyer H. Glucose-insulin-potassium in acute myocardial infarction: The time has come for a large, prospective trial. Circulation 96(4). 1074-1077.
43. Kornberg H.L. Anaplerotic sequences and their role in metabolism. Essays Biochem 1966; 2: 1-31.
44. Russell RR, III, Taegtmeyer H. Pyruvate carboxylation prevents the decline in contractile function of rat hearts oxidizing acetoacetate. Am J Physiol Heart Circ Physiol 1991; 261(6): 756-762.
45. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219-225.
46. Abramson DI, Schkloven N, Margolis MN, Mirsky IA. Influence of massive doses of insulin on peripheral blood flow in man. Am J Physiol 1939; 128(1): 124-132.
47. Baron AD, Brechtel G. Insulin differentially regulates systemic and skeletal muscle vascular resistance. Am J Physiol Endocrinol Metab 1993; 265(1): E61-E67.
48. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91(3): 764-770.
49. Furnary AP, Gao G, Grunkemeier GL, Wu YX, Zerr KJ, Bookin SO, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 125: 1007-21.
50. Kirdemir P, Yildirim V, Kiris I, Gulmen S, Kuralay E, Ibrisim E, et al. Does continuous insulin therapy reduce postoperative supraventricular tachycardia incidence after coronary artery bypass operations in diabetic patients? J Cardiothorac Vasc Anesth 2008; 22(3): 383-387.
51. Gandhi G, Nuttall GA, Abel MD, Mullany CJ, Schaff HV, O'Brien PC, et al. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med 2007; 146: 233-43.
52. Rao V, Christakis GT, Weisel RD, Ivanov J, Borger MA, Cohen G. The Insulin Cardioplegia Trial: Myocardial protection for urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 2002; 123(5): 928-935.
53. Degens H, Soop M, Hook P, Ljungqvist O and Larsson L. Post-operative effects on insulin resistance and specific tension of single human skeletal muscle fibres. Clin Sci (Lon) 1999; 97: 449-55.
54. Ceremuzynski L, Budaj A, Czepiel A, Burzykowski T, Achremczyk P, Smielak-Korombel W, et al. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drug Ther 1999; 13: 191-200.
55. Fishleder BL. Estudios experimentales a nivelcelular del tratamiento polarizante.3. la importancia del potasio Y de otros electrolitos en el proceso de contraccton de la fibra mioc'ardica. Arch Inst Cardiol Mex 1964; 34: 681.
56. Díaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MJ, Corvalán R, Isea JE, Romero G. Metabolic modulation of acute myocardial infarction: The ECLA glucose-insulin-potassium pilot trial. Circulation 1998; 98(21): 2227-2234.
57. Rogers WJ, Stanley AW, Breing JB, Prather JW, McDaniel HG, Moraski RE, et al. Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin-potassium infusion. Am Heart J 1976; 92: 441-454.
58. Albacker TB, Carvalho G, Schricker T, Lachapelle K. Highdose insulin therapy attenuates systemic inflammatory response in coronary artery bypass grafting patients. Ann Thorac Surg 2008; 86: 20-28.
59. Lecomte P, Foubert L, Nobels F, Coddens J, Nollet G, Casselman F, et al. Dynamic Tight Glycemic Control During and After Cardiac Surgery Is Effective, Feasible, and Safe. Anesth Analg 2008; 107(1): 51-58.
60. Lecomte P, Van Vlem B, Coddens J, Cammu G, Nollet G, Nobels F, et al. Tight perioperative glucose control is associated with a reduction in renal impairment and renal failure in non-diabetic cardiac surgical patients. Crit Care 2008; 12(6): R154.
61. Cochran S, Miller E, Dunn K, Burgess WP, Miles W, Lobdell K. Endotool (TM) software gor tight glucose control for critically ill patients. Crit Care Med 2006; 34 (S2): A68.
62. Boord JB, Sharifi M, Greevy RA, Griffin MR, Lee VK, Webb TA, et al. Computer-based insulin infusion protocol improves glycemia control over manual protocol. J Am Med Inform Assoc 2007; 14: 278-287.
63. Vogelzang M, Zijlstra F and Nijsten MWN. Design and implementation of GRIP: a computerized glucose control system at a surgical intensive care unit. BMC Med Inform Decis Mak 2005; 5: 38.
64. Saager L, Collins GL, Burnside B, Tymkew H, Zhang L, Jacobsohn E and Avidan M. A Randomized Study in Diabetic Patients Undergoing Cardiac Surgery comparing Computer-Guided Glucose Management With a Standard Sliding Scale Protocolhttp://www.jcvaonline.com/article/ S1053-0770(07)00289-3/abstract - article- footnote-1#article-footnote-1 Journal of Cardiothoracic and Vascular Anesthesia 2008; 22(3): 377-382.
65. Doenst T, Richwine RT, Bray MS, Goodwin GW, Frazier OH, Taegtmeyer H. Insulin improves functional and metabolic recovery of reperfused working rat heart. Ann Thorac Surg 1999; 67(6): 1682-1688.
66. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001; 89(12): 1191-1198.
67. Wistbacka JO, Nuutinen LS, Lepojarvi MV, Nissinen J, Karlqvist KE, Ruokonen A. Perioperative glucose-insulin-potassium infusion in elective coronary surgery: minor benefit in connection with blood cardioplegia? Infusionsther Transfusionsmed 1994; 21: 160-166.
68. Lazar HL, Zhang X, Rivers S, Bernard S, Shemin RJ. Limiting ischemic myocardial damage using glucose-insulin-potassium solutions. Ann Thorac Surg 1995; 60(2): 411-416.
69. Rao V, Borger MA, Weisel RD, Ivanov J, Christakis GT, Cohen G, et al. Insulin cardioplegia for elective coronary bypass surgery. J Thorac Cardiovasc Surg 2002; 119(6): 1176-1184.